| Date | Title | Description |
| 15.07.2026 | In Vivo CAR-T Startup Nava Emerges With $89M to Solve RNA Delivery’s Liver Problem | By Henry Baker
Published: Jul 15 2026, 1:49 PM EDT
Share on Facebook Share on Twitter Share on LinkedIn Share on Reddit Share on Flipboard |
| 21.06.2026 | Daily Stock Market Live
Stock futures are little changed as investors weigh Iran deal progress: Live updates | U.S. equity futures were little changed Monday as Wall Street assessed the latest developments in the Iran war negotiations and awaits the release of inflation data closely watched by the Federal Reserve.
S&P 500 futures traded down 0.1... |
| 19.06.2025 | Revolutionizing Cancer Treatment: Simcere Zaiming's Breakthrough in Multiple Myeloma Therapy | In the ever-evolving landscape of oncology, breakthroughs often emerge from the shadows of research labs. Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group, is stepping into the spotlight with its innovative therapy for relapsed... |
| 19.06.2025 | Simcere Zaiming Announces First Patient Dosed in the US in a Phase 1 Trial of Trispecific Antibody SIM0500 in Patients with Relapsed/Refractory Multiple Myeloma | SHANGHAI, June 19, 2025 /PRNewswire/ -- Simcere Zaiming, an innovative oncology-focused subsidiary of Simcere Pharmaceutical Group (2096.HK) today announced the first US patient has started treatment in the ongoing Phase 1 trial (SIM0500-10... |
| 12.05.2025 | U.S. politicians dump this pharma stock days before Trump’s drug price order | Summary
⚈ Two U.S. lawmakers sold AbbVie shares shortly before Trump’s drug price-cutting announcement, raising concerns about potential insider knowledge.
⚈ Trump’s May 13 executive order targets up to 80% reductions in drug costs, directl... |
| 14.01.2025 | Umoja secures $100M series C to bring more CAR-Ts into the clinic | Umoja Biopharma has secured $100 million in series C funds as the cancer-focused biotech looks to bring more of its cell therapies into the clinic.
Umoja’s only clinical-stage candidate is UB-TT170, a TumorTag-based treatment that tags soli... |
| 07.12.2023 | The tech billionaires trying to hack longevity and live forever | From Sam Altman (from top left, clockwise) to Peter Thiel, Mark Zuckerberg, Jeff Bezos, and Sergey Brin, many of the world's wealthiest billionaires seem to be on a quest for the fountain of youth. Lucy Nicholson/Reuters/Marco Bello/Getty I... |
| 27.10.2023 | Regeneron gene therapy improves hearing in child | Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Hi! Today we see that prime editing works nicely in monkeys, learn more about the potential new bill to speed treatm... |
| 06.05.2023 | Anal Botox patients explain how the procedure improved their sex lives | Health Anal Botox patients explain how the procedure improved their sex lives
Julia Naftulin
2023-05-06T09:23:00Z
Share icon An curved arrow pointing right.
Share
Facebook Icon The letter F.
Facebook Email icon An envelope. It indicates the... |
| 27.04.2023 | AbbVie Stock Falls as Humira Sales Drop | AbbVie shares took a tumble Thursday after the biopharmaceutical company said first-quarter sales of its anti-inflammatory drug Humira declined from a year ago.
AbbVie (ticker: ABBV) posted first-quarter net revenue of $12.23 billion, beati... |
| 28.02.2023 | Belly Wealth: One Founder Tackling The Most Undiagnosed & Dismissed Women’s Health Issue | Katie Wilson, CEO and founder of BelliWelli a brand that's placing probiotics in a brownie instead ... [+] of a pill.Courtesy of BelliWelli |
| 29.01.2023 | From Jeff Bezos to Jack Dorsey, here are 14 the world's wealthiest entrepreneurs trying to crack the code of living forever | Jeff Bezos is one among a handful of billionaires working to rewind the clock. Gareth Cattermole / Staff/ Getty Images
A growing number of the world's richest entrepreneurs are using their wealth to fight aging.
They're taking supplements, ... |
| 07.12.2022 | SEQSTER Named to the 2022 CB Insights Digital Health 150 List for the Second Consecutive Year | SEQSTER Named to the 2022 CB Insights Digital Health 150 List for the Second Consecutive Year
SEQSTER recognized for Powering Pharma & Life Sciences Industry with Patient-Centric Interoperability & Real-Time Real World Data
SAN DIEG... |
| 24.10.2022 | Digital health news, funding round up in the prior week; October 24, 2022 | Eli Lilly acquired Akouos; Tempus raised $275M; Calm launched Calm Health
Top Health News
Pfizer asked the Supreme Court to decide whether a proposed program to help Medicare patients pay out-of-pocket costs for its tafamidis drugs—Vyndaqel... |
| 07.07.2022 | Pharmacists 'ready to get to work' after new FDA authorization allows them to prescribe Pfizer's Covid-19 antiviral | When AbbVie chose to prop up its Allergan Aesthetics unit as a separate business post-merger, it set off some alarm bells that a spinoff or sale could be in the offing. But now, AbbVie is making an opportunistic play to boost the aesthetics... |
| 06.05.2022 | New Anti-Aging Vision Eye Drops Receive FDA Approval! Is This the Best Replacement for Eyeglasses and Contact Lenses? | Griffin Davis , Tech Times 06 May 2022, 01:05 pm
A new anti-aging vision eye drops received the approval of the U.S. Food and Drug Administration. Unlike other eye drops, which are usually used to treat irritation, this new model is designe... |
| 29.04.2022 | AbbVie Shares Drop Amid Missed Sales Expectations for Key Drugs | In a quarterly earnings report out Friday, the drugmaker AbbVie cut its full-year earnings guidance, and a number of its key drugs missed Wall Street estimates.
The company’s first-quarter earnings were roughly in line with Wall Street expe... |
| 14.04.2022 | AbbVie, Genmab tout early data for bispecific in a bid to leapfrog Regeneron, Roche | One of the key drugs on which AbbVie wagered $750 million cash to partner with Genmab has delivered stellar topline results, setting the stage for what the companies hope will be a speedy approval.
In a Phase I/II trial, Abb... |
| 14.04.2022 | AbbVie, Genmab tout early data for bispecific in a bid to leapfrog Regeneron, Roche | Relative to things like oncology and gene therapy, the field of hearing loss is small in the biotech world. When looking at hearing loss and regenerative medicine together, the space shrinks even further.
Now, the small, Oklahoma City-based... |
| 14.04.2022 | Let’s build something together: Ex-Lowe’s CFO to join Pfizer while Moderna’s David Meline retires; The CEO-partner party rolls on at Flagship | David Denton
→ The two major Covid-19 vaccine competitors, Pfizer and Moderna, will both have new finance chiefs within a week of each other: At Pfizer, David Denton will succeed 15-year vet Frank D’Amelio as CFO on May 2 af... |
| 14.04.2022 | AbbVie, Genmab tout early data for bispecific in a bid to leapfrog Regeneron, Roche | When Be Biopharma revealed itself a year and a half ago with $52 million, the Longwood-founded startup was confident about its vision of creating a new class of medicines out of B cells — but not quite sure yet where it would start. The com... |
| 13.04.2022 | After February market crash, ProQR will lay off 30% of its workforce and try pushing eye therapy after failed trial | A pivotal trial flop in February caused ProQR to lose nearly two-thirds of its stock value and that means the transatlantic company will officially join the dozens of biotechs and pharmas to lay off employees in the past few... |
| 13.04.2022 | AACR22: After FerGene blowup, a startup touts even better bladder cancer gene therapy results in tiny study | A private California biotech is raising some eyebrows on the final day of AACR22 as it reported interim data for its experimental drug in combination with Keytruda.
Looking at 18 patients with non-muscle-invasive bl... |
| 13.04.2022 | Bipartisan group of lawmakers call on 7 manufacturers to make opioid overdose antidote OTC | AbbVie president and vice chair Michael Severino is leaving the Chicago-area pharma giant on May 31 to become a CEO-partner at prolific biotech creator Flagship Pioneering in June. He’s the third CEO-partner to be named at the incubator, wh... |
| 13.04.2022 | The never-ending Zostavax story – in court. Merck gets a win, but thousands more lawsuits pending | A handful of prominent oncology pharmas are teaming up on a next-gen diagnostics initiative, with the ambitious vision of testing for all cancer patients. Bayer, GlaxoSmithKline, Novartis and Roche are leading the Precision Cancer Consortiu... |
| 13.04.2022 | The never-ending Zostavax story – in court. Merck gets a win, but thousands more lawsuits pending | Merck hasn’t sold Zostavax in the US since 2020, but that’s not stopping the lawsuits. Thousands of cases charging Zostavax side effects, efficacy issues and advertising and marketing complaints are still working their way... |
| 13.04.2022 | Turning Point looks to challenge Pfizer, Roche with new early data for lead lung cancer drug | Turning Point Therapeutics shared a Phase I/II update for its lead drug candidate repotrectinib, but investors said they were expecting slightly better.
In 71 total TKI-naive patients, the confirmed objective response ra... |
| 13.04.2022 | How McKinsey used its FDA connections to help opioid manufacturers: New congressional report | Though last September’s clinical hold on Protagonist Therapeutics was lifted after only a few weeks, the biotech quietly disclosed Wednesday that another FDA concern emerged from the pause.
US regulators intend to revoke the breakthrough th... |
| 15.12.2021 | Amid safety concerns, FDA grants two new JAK approvals — but with added warnings and a key label change | After a post-marketing trial for Pfizer’s Xeljanz turned up concerning safety results at the beginning of the year, thwarting the whole JAK class, the FDA is finally rolling out some new approvals — but with added warnings ... |
| 13.12.2021 | AbbVie’s Eye Drops Can Help Address Blurry Vision for Older People, Gets FDA Approval | Isaiah Richard, Tech Times 13 December 2021, 06:12 am
(Photo : Yaroslav Shuraev from Pexels)
AbbVie has released a new set of eye drops approved by the US Food and Drug Administration, aiming to help people with blurry vision. The focus of ... |
| 10.12.2021 | The first eye drops that sharpen close-up vision could replace reading glasses for millions of adults | Health The first eye drops that sharpen close-up vision could replace reading glasses for millions of adults
Andrea Michelson
2021-12-10T17:25:04Z
Share icon An curved arrow pointing right.
Share
Facebook Icon The letter F.
Facebook Email i... |
| 01.11.2021 | In key win, AbbVie lands FDA approval for Allergan's blurred-vision eye drop | AbbVie’s age-related blurry vision drug for aging adults was given the OK by the FDA Friday, making it the first eye drop to treat an eye condition that affects 128 million Americans.
Formerly AGN-190584, the drug has prov... |
| 01.11.2021 | Weeks into CEO shakeup, Mirati bids adieu to a pair of C-suiters with KRAS drug filing around the corner | Mirati is on the cusp of emerging as the sole challenger against Amgen in the suddenly hot KRAS inhibitor market and thinks it has the man to take it across the finish line. But new leadership often means shakeups, and now two ... |
| 01.11.2021 | Tal Zaks' post-Moderna future is now in view as he joins biotech VC blue-chipper OrbiMed | It’s hard to imagine what comes next for a physician-scientist who’s developed one of the most lucrative vaccines in biopharma history. On Monday — a month after leaving his post at Moderna — Tal Zaks cleared up some of th... |
| 01.11.2021 | With the help of the NY governor's office, Strides Pharma acquires new manufacturing site | For a long time, migraine sufferers were stuck with the same old medicines and advice. Try some triptans, change your diet, maybe even see if a narcotic might help — but no major drug advances to prevent or stop debilitating migraine episod... |
| 01.11.2021 | With the help of the NY governor's office, Strides Pharma acquires new manufacturing site | The 2016 meeting of the Oligonucleotide Therapeutics Society in Montreal began with a rare mix of promise and elation.
That year, the 27-year-old biotech Ionis showed that a drug, later branded Spinraza, could dramatically alter the course ... |
| 01.11.2021 | Perceptive steers LianBio's globally connected China strategy to $325M IPO | LianBio was founded to tackle a big mission: to take the in-licensing strategy that’s been popularized in China over the past decade and supercharge it with rich global connections and a creative approach to dealmaking.... |
| 01.11.2021 | With the help of the NY governor's office, Strides Pharma acquires new manufacturing site | An Indian biopharma has seen its US business increase accordingly as it’s expanded its portfolio, and the company is acquiring a manufacturing site on the New York/New Jersey border to up annual capacity and avoi... |
| 01.11.2021 | With the help of the NY governor's office, Strides Pharma acquires new manufacturing site | Merck’s $11.5 billion Acceleron Pharma buyout may not happen quite as soon as the Kenilworth, NJ-based pharma company had hoped.
On Friday, Merck revealed that it had temporarily withdrawn its premerger notification and report form — which ... |
| 01.11.2021 | Merck dives even further into cytokine research as deal spree continues | Merck’s new leadership hasn’t been shy about its desire to spend, agreeing to drop $11.5 billion on a new biotech and promising to dole out more as the expiration date on the company’s money machine slowly approaches.
On Mo... |
| 20.10.2021 | FDA approves Humira biosimilar as first-ever interchangeable monoclonal antibody | AbbVie’s blockbuster drug Humira has more competition coming—the first FDA-approved biosimilar that may be substituted for the monoclonal antibody at the pharmacy. The competing Boehringer Ingelheim product is only the second interchangeabl... |
| 07.10.2021 | Schrödinger teams up with MD Anderson on WEE1 inhibitor program; Amid JAK safety concerns, AbbVie touts new data for Rinvoq | Physics-based discovery outfit Schrödinger and the University of Texas MD Anderson Cancer Center announced today a two-year research collaboration — focused on accelerating and optimizing development of Schröding... |
| 15.09.2021 | Not so fast: FDA tacks 3 more months onto decision date for Calliditas' rare kidney disorder drug | It looks like the FDA’s decision on Calliditas’ IgA nephropathy candidate Nefecon is going to take a few months longer than expected — allowing time for rivals like Martin Shkreli’s former company Travere Therapeuti... |
| 13.09.2021 | AbbVie Nabs Eye Disease Gene Therapy From Regenxbio for Up to $1.8 Billion | AbbVie said Monday that it would pay the biotech Regenxbio up to $1.8 billion for a share of the potential profits from sales of the company’s experimental gene therapy to treat a variety of eye diseases.
AbbVie (ticker: ABBV) shares were u... |
| 12.08.2021 | AbbVie : Ventures Launches Inaugural AIM Award | AbbVie Ventures is excited to announce the launch of its inaugural AbbVie Innovation Midwest (AIM) Award, an incubator program designed to enable emerging scientists, researchers and biotech entrepreneurs working on novel science with poten... |
| 30.03.2021 | Forma sees data 'supporting' sickle cell therapy dosing levels; LianBio teams with Tarsus for eye irritation in China | Looking to make a splash in sickle cell, Forma Therapeutics presented new data they hope can improve their shot at an eventual FDA OK.
As part of an ongoing Phase I study, Forma said its FT-4202 program showed enough hemog... |
| 18.03.2021 | ADVERUM BIOTECHNOLOGIES, INC.
Adverum Biotechnologies : Announces Board Slate for 2021 Annual Meeting and Reiterates Commitment to Stockholder Value Creation | Responds to Intent to Nominate Directors from Sonic Fund
Sonic’s Attempt to Control the Board Not in the Best Interests of Adverum or the Company’s Stockholders
REDWOOD CITY, Calif., March 17, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologie... |
| 17.03.2021 | Adverum Biotechnologies : Announces Board Slate for 2021 Annual Meeting and Reiterates Commitment to Stockholder Value Creation | Responds to Intent to Nominate Directors from Sonic Fund
Sonic’s Attempt to Control the Board Not in the Best Interests of Adverum or the Company’s Stockholders
REDWOOD CITY, Calif., March 17, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologie... |
| 19.02.2021 | Incyte scores speedy FDA review for JAK cream in atopic dermatitis; Lilly backs $90M raise for Regor | Incyte’s stalwart JAK inhibitor Jakafi has raced out to blockbuster sales without the safety burden of other drugs in the class. Now, the drugmaker’s quest to reformulate the drug for easier use could be nearing fruition — b... |
| 19.02.2021 | AbbVie puts an end to Botox trade secrets suit, imposes royalty, license deal on competitor Evolus | The crown jewel of AbbVie’s big-dollar acquisition of Allergan, Botox is one of the most recognizable brands in pharma — and both drugmakers have worked overtime to protect its advantage. After scoring a fatal blow to ... |
| 19.02.2021 | UPDATED: After crossing t's, dotting i's, Immunocore nails down breakthrough therapy designation for lead TCR therapy | Welcome to the second installment of Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New ... |
| 18.02.2021 | Mallinckrodt becomes the latest victim of the FDA's pandemic-related delays as it pushes off application for skin graft | With Covid-19 locking down travel across the world, not even drug safety regulators have been spared from costly delays. For the FDA, whose inspection schedule keeps the trains on time for new marketing approvals, those delay... |
| 05.01.2021 | AbbVie eyes Humira matching move into psoriatic arthritis for immunology follow-up Skyrizi | Pharma borg AbbVie hasn’t had many roadblocks on its path to dominance with megablockbuster Humira regularly topping pharma’s bestseller list. But Humira’s days on top are numbered, and AbbVie is making the case for new... |
| 09.12.2020 | AbbVie chases its next golden goose in a post-Humira future with new ulcerative colitis data for Rinvoq | Still bathing in the afterglow of its big-money acquisition of Allergan, AbbVie faces the dark cloud of a post-Humira future — and the deadline is approaching fast. Key to AbbVie’s plan are two immunology launches with... |
| 14.11.2020 | Symptoms of endometriosis and how you can manage the pain
Related stories about women's health: | Reviews Chevron icon It indicates an expandable section or menu, or sometimes previous / next navigation options.
Health Symptoms of endometriosis and how you can manage the pain
Written by Jennifer Larson; edited by Jessica Orwig
Updated
2... |
| 11.11.2020 | Inipharm raises $35M to combat liver diseases with a genetics approach | Liver diseases, including fatty liver disease, cirrhosis and various rare diseases, have differing causes, from viruses, to drugs, to alcohol, to genetics. However, many of these diseases share effects, including inflammation and fibrosis, ... |
| 11.11.2020 | Inipharm raises $35M to combat liver diseases with a genetics approach
W h i t e p a p e r
Weighing the Costs: | Liver diseases, including fatty liver disease, cirrhosis and various rare diseases, have differing causes, from viruses, to drugs, to alcohol, to genetics. However, many of these diseases share effects, including inflammation and fibrosis, ... |
| 11.08.2020 | Antibody drugs could be one of the best weapons against Covid-19. But will they matter? | From the moment Covid-19 emerged as a threat, one approach to making drugs to treat or prevent the disease seemed to hold the most promise: They’re known as monoclonal antibodies.
Now, scientists are on the brink of getting important data t... |
| 04.08.2020 | AbbVie shrugs off $134M cash deals, quitting a neuro R&D pact with Voyager Therapeutics on vectorized antibody treatments | It’s the end of the road for Voyager Therapeutics’ collaboration with AbbVie on tau and alpha-synuclein vectorized antibody development.
In two deals spanning the last two years, AbbVie dropped more than $134 million... |
| 10.06.2020 | AbbVie, Denmark’s Genmab enter nearly $4B cancer immunotherapy partnership | Under the terms of the deal, AbbVie will pay Genmab $750 million upfront, along with up to $3.15 billion in milestone payments.
Shares of Genmab were up 4.6% Wednesday afternoon on Nasdaq Nordic’s Copenhagen exchange, trading at around 1,96... |
| 09.06.2020 | FDA Approves First Oral Treatment For Heavy Menstrual Bleeding Due To Uterine Fibroids | Shot of a young woman suffering from stomach cramps in her bedroomGetty |
| 02.06.2020 | It’s time to bring generic drug manufacturing back to the U.S. | In a hearing Tuesday afternoon on Capitol Hill, policymakers will consider repatriating America’s drug supply chain to avoid future shortages like the ones caused by Covid-19. They should think bigger.
Repatriating the American drug supply ... |
| 22.04.2020 | AbbVie, J&J blockbuster Imbruvica rakes in 11th FDA approval, as competitors work on eroding franchise | AbbVie and J&J’s market-leading Imbruvica, the original BTK inhibitor, continues to rake in approvals, while competition in the class of drugs heats up.
On Tuesday, the drug secured its 11th FDA approval. Imbruvica... |
| 01.04.2020 | Coronavirus Business Tracker: How The Private Sector Is Fighting The Covid-19 Pandemic | Alain Mérieux, founder of BioMérieux.AFP via Getty Images |
| 25.03.2020 | AbbVie, Roche leukemia drug successful in Phase III confirmatory study | In late 2018, Venclexta won an accelerated approval from the Food and Drug Administration for frontline AML, in combination with Vidaza, among patients aged 75 and older. VIALE-A and another study, VIALE-C – combining the drug with low dose... |
| 06.03.2020 | European regulators expand use of AbbVie's two-month hep C regimen | The landscape of hepatitis C — once a devastating liver-damaging disease — has changed dramatically since 2014, when the first raft of new therapies ushered in an era that has culminated in potential cure rates of more... |
| 04.03.2020 | Israeli scientists work to test adapted avian flu vaccine against human coronavirus | Israeli scientists have announced that a new vaccine they developed for a deadly virus affecting poultry could be adapted for human use against the novel coronavirus known as SARS-CoV-2. This coronavirus causes the disease called COVID-19, ... |
| 18.02.2020 | Consumer groups and unions try again to block the AbbVie and Allergan merger | A coalition of consumer groups and unions hopes to convince the Federal Trade Commission to alter the terms of AbbVie’s (ABBV) proposed $63 billion acquisition of Allergan (AGN) by arguing the deal — as currently conceived — would thwart co... |
| 27.01.2020 | Allergan to divest two drugs to satisfy regulators in $63B acquisition by AbbVie | A drugmaker in one of the largest acquisition deals announced last year is offloading an investigational treatment for autoimmune disease and an approved drug for a pancreatic disorder in order to satisfy federal antitrust requirements.
Chi... |
| 22.10.2019 | Where are the interchangeable biosimilars? | In June 2017, Leah Christl, former biosimilar lead at FDA, told a conference in Chicago that interchangeable biosimilars were likely coming to the US market within two years.
And although no interchangeable biosimilar h... |
| 19.08.2019 | FDA approves AbbVie rheumatoid arthritis drug | Shares of AbbVie were up 2.8 percent Monday morning on the New York Stock Exchange following the news. Reuters reported that the drug would carry a list price of $59,000 per year.
AbbVie’s top-selling drug is Humira (adalimumab), which is a... |
| 16.05.2019 | AbbVie/Roche's Venclexta wins fourth approval; WuXi, fellow CRO Altasciences ink deal | Michael Severino
→ AbbVie and Roche’s blood cancer drug, Venclexta, has notched a fourth approval. On Wednesday, AbbVie $ABBV said the drug was approved in combination with Genentech’s Gazyva for treatment-naive patients... |
| 03.05.2019 | FDA expands approval of Agios' Tibsovo; AstraZeneca's long-acting diabetes drug secures US nod | → Tibsovo is Agios’ first wholly-owned product, second approved therapy and the last drug that founder David Schenkein saw across the finish line before handing over the reins to Jackie Fouse. Like the 2017-approved Idhifa, T... |
| 24.04.2019 | Anxious to fill Humira-sized revenue hole ahead of US patent cliff, AbbVie hits the ground running with FDA approval for Skyrizi | With the looming cloud of losing US patent protection for its mega-blockbuster Humira, AbbVie needs all the help it can get to fill the gaping $20 billion hole the flagship autoimmune disease drug will leave in its coffers. ... |
| 31.03.2019 | Gilead, Galapagos’s filgotinib scores in Phase III rheumatoid arthritis trial, but questions remain | Gilead’s shares rose 3 percent Friday morning following the news, while Galapagos’s shares were up 25 percent by the early afternoon.
Filgotinib is a JAK inhibitor and in almost neck-and-neck competition against AbbVie’s upadacitinib, which... |
| 26.02.2019 | Senate committee panel puts drug industry CEOs on defensive over pricing | As executives sat expressionless, Wyden unleashed a harsh critique of their companies and business practices.
He singled out Chicago-based AbbVie for what he called unfair protection of its patents on Humira (adalimumab), a drug for autoimm... |
| 24.07.2018 | A new treatment for a condition that can feel like tiny people skating on razor blades in your stomach and affects an estimated 200 million women just got approved | Reuters
Instead of turning to surgery, drugmakers are hoping to treat diseases like uterine fibroids and endometriosis with new medications.
Advertisement
The FDA just approved elagolix, a new treatment for women living with endometriosis.
... |
| 02.07.2018 | AbbVie spent billions on a buzzy Silicon Valley cancer drug company. Now Wall Street's calling the deal a 'dud.' | Flickr/Ed Uthman
Advertisement
The cancer-stem-cell company Stemcentrx was one of the biggest venture capital-backed deals in history when it was acquired in 2016 for over $10 billion. But it hasn't seen the blockbuster success its big pric... |
| 13.03.2018 | AbbVie sweeps back-to-back PhIIIs for uterine fibroid patients, adding to elagolix's blockbuster rep | AbbVie is on a roll.
The pharma giant $ABBV has rolled up its second and final positive Phase III for elagolix, one of its top blockbuster hopefuls that is now being pointed to the FDA in search of a near-term approval for tre... |
| 21.02.2018 | AbbVie rolls up another big win for elagolix as the prospective blockbuster sweeps endpoints in latest PhIII | Already on the fast priority track at the FDA with their application to start selling elagolix for endometriosis, AbbVie $ABBV said today that the drug also came through with flying colors in the first of two pivotal tria... |
| 27.10.2017 | Brushing back biosims, a confident AbbVie outlines a blockbuster winning streak ahead for Humira | While Gilead and Celgene were showing just how significant new pricing competition can be in destroying their forecasting abilities, AbbVie showed up Friday morning with a revenue projection that underscores just how... |
| 20.03.2017 | A small drug company that's trying to make cancer treatments safer just received a huge endorsement | REUTERS/Suzanne Plunkett
A tray containing cancer cells sits on an optical microscope in the Nanomedicine Lab at UCL's School of Pharmacy in London.
CytomX, a biotech that's developing safer ways to administer cancer immunotherapies, just g... |
| 17.01.2017 | Pharma companies routinely bend orphan drug rules | But lucrative financial incentives created by the Orphan Drug Act signed into law by President Ronald Reagan in 1983 succeeded far beyond anyone’s expectations. More than 200 companies have brought almost 450 “orphan drugs” to market since ... |
| 06.12.2016 | GSK vet Deborah Waterhouse takes CEO spot at Viiv; Is Sanofi pondering an Actelion bid? | Deborah Waterhouse
GSK insider Deborah Waterhouse, currently an SVP running the primary care ops of the US pharma division, has been tapped as the new CEO of Viiv, an ambitious joint venture focused on HIV. A 20-year ... |
| - | Gilead, Galapagos’s filgotinib scores in Phase III rheumatoid arthritis trial, but questions remain | Biotech giant Gilead Sciences and a European partner scored a win Thursday with a positive Phase III study of a new drug in rheumatoid arthritis, but analysts say they still have challenges they’ll have to overcome.
Foster City, California-... |
| - | Allergan to divest two drugs to satisfy regulators in $63B acquisition by AbbVie | A drugmaker in one of the largest acquisition deals announced last year is offloading an investigational treatment for autoimmune disease and an approved drug for a pancreatic disorder in order to satisfy federal antitrust requirements.
Chi... |
| - | FDA approves AbbVie rheumatoid arthritis drug | The Food and Drug Administration has approved a new drug for rheumatoid arthritis made by AbbVie.
The Chicago-based drugmaker said Friday that the FDA had approved Rinvoq (upadacitinib) for patients with moderately to severely active RA who... |
| - | Biotech stocks jump on AbbVie deal to buy cancer drugmaker ImmunoGen for $10 billion | Biotech stocks rose as AbbVie announced plans to buy cancer drug developer ImmunoGen for $10 billion.
Shares of ImmunoGen, which develops cancer treatments called antibody-drug conjugates, closed nearly 83% higher.
Other biotech companies d... |
| - | Senate committee panel puts drug industry CEOs on defensive over pricing | Several pharmaceutical executives said in a Senate committee hearing Tuesday that if they are to lower list prices on their drugs in a meaningful way, the government will have to step in.
The Senate Finance Committee hearing was the second ... |
| - | AbbVie, Roche leukemia drug successful in Phase III confirmatory study | A cancer drug made by Chicago-based AbbVie and Swiss drugmaker Roche was successful in a Phase III confirmatory trial in an aggressive form of leukemia less than a month after failing in another study.
AbbVie and Roche said Monday that the ... |
| - | Meet The Top 100 Investors On Forbes Midas List | Image Credits
Just like every year, Forbes magazine has released the 2017 Midas List including the top 100 tech venture capital investors.
It’s hard for a VC to stay on top of their game. It requires an appetite for risk, immense calculatio... |
| - | AbbVie, Denmark’s Genmab enter nearly $4B cancer immunotherapy partnership | One of the largest drugmakers in the U.S. is partnering with a Danish firm to develop antibody-based therapies in oncology.
Chicago-based AbbVie and Copenhagen-based Genmab said Wednesday that they had formed the partnership that will focus... |
| - | Buy these 7 dividend stocks for extra income as inflation erodes purchasing power, says a fund manager who has performed better than 96% of his competitors this year | Dividend stocks provide income as inflation — and recession risk —rises. Eva-Katalin/Getty This story is available exclusively to Insider subscribers. Become an Insider and start reading now.
Mike Morey, who runs the Integrity Dividend Harv... |
| - | FDA approves Humira biosimilar as first-ever interchangeable monoclonal antibody | AbbVie’s blockbuster drug Humira has more competition coming—the first FDA-approved biosimilar that may be substituted for the monoclonal antibody at the pharmacy. The competing Boehringer Ingelheim product is only the second interchangeabl... |
| - | Pharma companies routinely bend orphan drug rules | More than 30 years ago, Congress overwhelmingly passed a landmark health bill aimed at motivating pharmaceutical companies to develop new drugs for people whose rare diseases had been ignored.
By the drugmakers’ calculations, the markets fo... |